GlassScriptPhysician profile
Julie Eileen Roat
NPI 1114400660
$6,432.43
in general payments reported to CMS, 2019-2025
23 companies · $1,991 in 2025
The $1,991 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $851 · 2022: $910 · 2023: $1,863 · 2024: $817 · 2025: $1,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,748 · Travel and Lodging: $1,896 · Education: $28.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,747.54 |
| Travel and Lodging | $1,895.51 |
| Education | $28.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,787.34 | 2021-2025 | Corevalve Evolut R |
| Edwards Lifesciences Corporation | $1,704.57 | 2021-2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $262.71 | 2022-2023 | Farxiga, Brilinta |
| Actelion Pharmaceuticals US, INC. | $252.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $186.15 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $173.91 | 2022 | |
| Abiomed | $148.87 | 2023 | Impella |
| Si-Bone, INC. | $126.13 | 2021 | |
| Paratek Pharmaceuticals, INC. | $116.61 | 2022 | |
| Amgen INC. | $95.09 | 2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $77.88 | 2024 | |
| Glaxosmithkline, LLC. | $71.32 | 2023 | Nucala |
| Inari Medical, INC. | $69.04 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $64.79 | 2022-2023 | |
| Biogen, INC. | $64.57 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $54.53 | 2022 | |
| Pfizer INC. | $50.94 | 2022 | |
| Abbott Laboratories | $30.18 | 2022-2024 | Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.10 | 2022-2025 | Lifevest |
| Genzyme Corporation | $21.73 | 2024 | |
| Itamar Medical INC | $17.20 | 2023 | Watchpatone |
| Esperion Therapeutics, INC. | $14.91 | 2023 | Nexletol |
| Teleflex LLC | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Roat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.